Compare JMSB & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JMSB | AGEN |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.2M | 274.8M |
| IPO Year | 2022 | 1999 |
| Metric | JMSB | AGEN |
|---|---|---|
| Price | $23.32 | $6.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $23.00 | $14.50 |
| AVG Volume (30 Days) | 30.1K | ★ 8.2M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | 24.17 | ★ 100.00 |
| EPS | 0.93 | ★ 1.02 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | $17.09 | $107.63 |
| Revenue Next Year | $10.03 | N/A |
| P/E Ratio | $54.30 | ★ $7.34 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $18.50 | $2.71 |
| 52 Week High | $24.26 | $8.85 |
| Indicator | JMSB | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 59.22 | 66.62 |
| Support Level | $20.72 | $3.09 |
| Resistance Level | N/A | $8.70 |
| Average True Range (ATR) | 0.77 | 0.74 |
| MACD | 0.08 | 0.12 |
| Stochastic Oscillator | 65.15 | 65.22 |
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.